ARTIFICIAL INTELLIGENCE–ASSISTED DRUG DISCOVERY: RECENT ADVANCES IN LEAD IDENTIFICATION AND OPTIMIZATION

Authors

  • Dr. Adrian Keller Department of Medicinal Chemistry and Computational Drug Design, European Institute of Pharmaceutical Sciences, Berlin, Germany

Keywords:

artificial intelligence; drug discovery; machine learning; deep learning; virtual screening; lead optimization; ADMET; generative models.

Abstract

Artificial intelligence (AI) has moved from a largely exploratory technology in pharmaceutical research to a practical set of methods for molecular representation, virtual screening, de novo design, structure prediction, property forecasting and multi-parameter lead optimization. The present study provides a structured narrative review of recent advances in AI-assisted small-molecule drug discovery, with particular emphasis on the transition from hit identification to experimentally actionable lead series. Fifteen peer-reviewed international publications from 2018–2026 were selected to represent major methodological and translational milestones. The reviewed evidence shows that graph neural networks, self-supervised molecular representations, chemical language models, reinforcement learning, deep quantitative structure–activity relationship models and structure-prediction systems can improve prioritization across large chemical spaces and support iterative medicinal chemistry decisions. Prospective examples include the rapid generation of DDR1 kinase inhibitors and deep-learning-guided identification of the structurally distinct antibiotic halicin. AlphaFold2 and AlphaFold3 further expanded the structural information available for target assessment and biomolecular interaction modeling. However, benchmark performance does not automatically translate into clinical value. Data quality, dataset shift, uncertainty calibration, interpretability, synthetic feasibility, experimental validation and the choice of biologically meaningful endpoints remain decisive constraints. The most defensible near-term model is therefore not autonomous drug discovery, but a closed-loop human–AI workflow in which algorithms prioritize experiments, new assay data update the models and medicinal chemists retain control over multi-objective trade-offs. This framework can shorten design–make–test–analyze cycles while preserving scientific accountability and translational relevance.

 

References

1. Vamathevan, J., Clark, D., Czodrowski, P., et al. Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery. 2019;18:463–477. https://doi.org/10.1038/s41573-019-0024-5

2. Schneider, P., Walters, W. P., Plowright, A. T., et al. Rethinking drug design in the artificial intelligence era. Nature Reviews Drug Discovery. 2020;19:353–364. https://doi.org/10.1038/s41573-019-0050-3

3. Wu, Z., Ramsundar, B., Feinberg, E. N., et al. MoleculeNet: a benchmark for molecular machine learning. Chemical Science. 2018;9:513–530. https://doi.org/10.1039/C7SC02664A

4. Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nature Biotechnology. 2019;37:1038–1040. https://doi.org/10.1038/s41587-019-0224-x

5. Stokes, J. M., Yang, K., Swanson, K., et al. A deep learning approach to antibiotic discovery. Cell. 2020;180(4):688–702.e13. https://doi.org/10.1016/j.cell.2020.01.021

6. Jiménez-Luna, J., Grisoni, F., & Schneider, G. Drug discovery with explainable artificial intelligence. Nature Machine Intelligence. 2020;2:573–584. https://doi.org/10.1038/s42256-020-00236-4

7. Bender, A., & Cortés-Ciriano, I. Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet. Drug Discovery Today. 2021;26(2):511–524. https://doi.org/10.1016/j.drudis.2020.12.009

8. Jumper, J., Evans, R., Pritzel, A., et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583–589. https://doi.org/10.1038/s41586-021-03819-2

9. Wang, Y., Wang, J., Cao, Z., et al. Molecular contrastive learning of representations via graph neural networks. Nature Machine Intelligence. 2022;4:279–287. https://doi.org/10.1038/s42256-022-00447-x

10. Fang, X., Liu, L., Lei, J., et al. Geometry-enhanced molecular representation learning for property prediction. Nature Machine Intelligence. 2022;4:127–134. https://doi.org/10.1038/s42256-021-00438-4

11. Mokaya, M., Imrie, F., van Hoorn, W. P., et al. Testing the limits of SMILES-based de novo molecular generation with curriculum and deep reinforcement learning. Nature Machine Intelligence. 2023;5:386–394. https://doi.org/10.1038/s42256-023-00636-2

12. Li, H., Zou, L., Kowah, J. A. H., et al. A compact review of progress and prospects of deep learning in drug discovery. Journal of Molecular Modeling. 2023;29(4):117. https://doi.org/10.1007/s00894-023-05492-w

13. Tropsha, A., Isayev, O., Varnek, A., Schneider, G., & Cherkasov, A. Integrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR. Nature Reviews Drug Discovery. 2024;23:141–155. https://doi.org/10.1038/s41573-023-00832-0

14. Abramson, J., Adler, J., Dunger, J., et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024;630:493–500. https://doi.org/10.1038/s41586-024-07487-w

15. Mohamed, F. A. A. A., & El-Sagheir, A. M. K. Artificial intelligence-assisted lead optimization in drug discovery: bridging computational advances and translational challenges. Medicinal Chemistry Research. 2026. Online ahead of print. https://doi.org/10.1007/s00044-026-03616-4

Published

2026-09-20